Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Anti-FAP scFv from clone BIBH 1 (sibrotuzumab) with that of the anti-CD3 scFV LK2-07 (blinatumomab) |
Target |
Action stimulants, antagonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), FAP antagonists(Fibroblast activation protein alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteosarcoma | Preclinical | United States | 14 May 2025 |






